Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 58

1.

Molecular predictive and prognostic markers in colon cancer.

Winder T, Lenz HJ.

Cancer Treat Rev. 2010 Nov;36(7):550-6. doi: 10.1016/j.ctrv.2010.03.005. Epub 2010 Apr 3. Review.

PMID:
20363564
2.
3.

Overview of resistance to systemic therapy in patients with breast cancer.

Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN.

Adv Exp Med Biol. 2007;608:1-22. Review.

PMID:
17993229
4.

The role of molecular markers in predicting response to therapy in patients with colorectal cancer.

Shankaran V, Wisinski KB, Mulcahy MF, Benson AB 3rd.

Mol Diagn Ther. 2008;12(2):87-98. Review.

PMID:
18422373
5.

A review on the use of molecular markers of cytotoxic therapy for colorectal cancer, what have we learned?

Koopman M, Venderbosch S, Nagtegaal ID, van Krieken JH, Punt CJ.

Eur J Cancer. 2009 Jul;45(11):1935-49. doi: 10.1016/j.ejca.2009.04.023. Epub 2009 May 25. Review.

PMID:
19473832
6.

Biological prognostic and predictive factors in lung cancer.

Rossi A, Galetta D, Gridelli C.

Oncology. 2009;77 Suppl 1:90-6. doi: 10.1159/000258500. Epub 2010 Feb 2. Review.

PMID:
20130436
7.

Understanding the predictive role of K-ras for epidermal growth factor receptor-targeted therapies in colorectal cancer.

Ramos FJ, Macarulla T, Capdevila J, Elez E, Tabernero J.

Clin Colorectal Cancer. 2008 Dec;7 Suppl 2:S52-7. doi: 10.3816/CCC.2008.s.008. Review.

PMID:
19064407
8.

Genetic prognostic and predictive markers in colorectal cancer.

Walther A, Johnstone E, Swanton C, Midgley R, Tomlinson I, Kerr D.

Nat Rev Cancer. 2009 Jul;9(7):489-99. doi: 10.1038/nrc2645. Epub 2009 Jun 18. Review. Erratum in: Nat Rev Cancer. 2011 Apr;11(4):309.

PMID:
19536109
9.

[Pharmacogenetic studies on the prediction of efficacy and toxicity of fluoropyrimidine-based adjuvant therapy in colorectal cancer].

Kralovánszky J, Adleff V, Hitre E, Pap E, Réti A, Komlósi V, Budai B.

Magy Onkol. 2007;51(2):113-25. Epub 2007 Jul 29. Hungarian.

10.

Potential predictive markers of response to EGFR-targeted therapies in colorectal cancer.

Spano JP, Milano G, Vignot S, Khayat D.

Crit Rev Oncol Hematol. 2008 Apr;66(1):21-30. doi: 10.1016/j.critrevonc.2007.11.005. Epub 2008 Feb 21. Review.

PMID:
18206383
11.
12.

Role of pharmacogenetics as predictive biomarkers of response and/or toxicity in the treatment of colorectal cancer.

Bhushan S, McLeod H, Walko CM.

Clin Colorectal Cancer. 2009 Jan;8(1):15-21. doi: 10.3816/CCC.2009.n.003. Review.

PMID:
19203892
13.

Enhancing oxaliplatin-based regimens in colorectal cancer by inhibiting the epidermal growth factor receptor pathway.

Kim GP, Grothey A.

Clin Colorectal Cancer. 2005 Nov;5 Suppl 2:S89-97. Review.

PMID:
16336754
14.

Predictive value of thymidylate synthase and dihydropyrimidine dehydrogenase protein expression on survival in adjuvantly treated stage III colon cancer patients.

Westra JL, Hollema H, Schaapveld M, Platteel I, Oien KA, Keith WN, Mauritz R, Peters GJ, Buys CH, Hofstra RM, Plukker JT.

Ann Oncol. 2005 Oct;16(10):1646-53. Epub 2005 Jul 12.

15.

Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression levels: predictors for survival in colorectal cancer patients receiving adjuvant 5-fluorouracil.

Kornmann M, Schwabe W, Sander S, Kron M, Sträter J, Polat S, Kettner E, Weiser HF, Baumann W, Schramm H, Häusler P, Ott K, Behnke D, Staib L, Beger HG, Link KH.

Clin Cancer Res. 2003 Sep 15;9(11):4116-24.

16.

Thymidine phosphorylase, dihydropyrimidine dehydrogenase and thymidylate synthase mRNA expression in primary colorectal tumors-correlation to tumor histopathology and clinical follow-up.

Lassmann S, Hennig M, Rosenberg R, Nährig J, Schreglmann J, Krause F, Poignee-Heger M, Nekarda H, Höfler H, Werner M.

Int J Colorectal Dis. 2006 Apr;21(3):238-47. Epub 2005 Aug 13.

PMID:
16132996
17.

Palliative treatment of unresectable metastatic colorectal cancer.

Fornaro L, Masi G, Loupakis F, Vasile E, Falcone A.

Expert Opin Pharmacother. 2010 Jan;11(1):63-77. doi: 10.1517/14656560903427997. Review.

PMID:
20001430
18.

Phase II study of tailored chemotherapy for advanced colorectal cancer with either 5-fluouracil and leucovorin or oxaliplatin and irinotecan based on the expression of thymidylate synthase and dihydropyrimidine dehydrogenase.

Smorenburg CH, Peters GJ, van Groeningen CJ, Noordhuis P, Smid K, van Riel AM, Dercksen W, Pinedo HM, Giaccone G.

Ann Oncol. 2006 Jan;17(1):35-42. Epub 2005 Oct 26.

19.

Prognostic role of serum vascular endothelial growth factor, basic fibroblast growth factor and nitric oxide in patients with colorectal carcinoma.

Akbulut H, Altuntas F, Akbulut KG, Ozturk G, Cindoruk M, Unal E, Icli F.

Cytokine. 2002 Nov 24;20(4):184-90.

PMID:
12543084
20.

K-Ras mutations and treatment outcome in colorectal cancer patients receiving exclusive fluoropyrimidine therapy.

Etienne-Grimaldi MC, Formento JL, Francoual M, François E, Formento P, Renée N, Laurent-Puig P, Chazal M, Benchimol D, Delpero JR, Letoublon C, Pezet D, Seitz JF, Milano G.

Clin Cancer Res. 2008 Aug 1;14(15):4830-5. doi: 10.1158/1078-0432.CCR-07-4906.

Items per page

Supplemental Content

Write to the Help Desk